Wednesday, July 8, 2026

Patent intelligence · US

US 12377093

Pyruvate kinase activators for use in therapy

granted A61KA61K31/415A61K31/4406A61K31/47
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 93
Patent details — US 12377093
Jurisdiction
US
Status
granted
Grant date
Aug 5, 2025
Expiration
Jul 31, 2045
Claims
16
CPC classes
A61K, A61K31/415, A61K31/4406, A61K31/47
View on Google Patents ↗

Quick answer

US 12377093 (Pyruvate kinase activators for use in therapy) is held by Agios Pharmaceuticals, Inc.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K31/415, A61K31/4406, A61K31/47, A61K31/496, A61K31/4965

More from Agios Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12428376

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Expires Sep 25, 2045

    granted
  2. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Expires Oct 31, 2044

    granted
  3. US 11957680

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Expires Apr 11, 2044

    granted
  4. US 11919915

    Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

    Agios Pharmaceuticals, Inc. · Expires Feb 29, 2044

    granted
  5. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Agios Pharmaceuticals, Inc. · Expires Jan 18, 2044

    granted
  6. US 11872225

    Pyruvate kinase modulators and use thereof

    Agios Pharmaceuticals, Inc. · Expires Jan 11, 2044

    granted
  7. US 11866411

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Expires Jan 4, 2044

    granted

Frequently asked questions

What is US patent 12377093?

US 12377093 (Pyruvate kinase activators for use in therapy) is held by Agios Pharmaceuticals, Inc.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12377093?

Agios Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 93 pharmaceutical patents for this assignee.

When does US 12377093 expire?

Our index shows an expiration date of Jul 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.